New weight-loss drug on its way to Israel: Everything you need to know
Significant news for those looking to lose weight: pharmaceutical company Eli Lilly has announced that its new weight-loss drug, "Foundayo" (orforglipron), is expected to arrive at pharmacies in Israel as early as September 15, immediately following the holiday season.
The new drug joins a variety of medical solutions already on the market, but it is considered one of the most talked-about developments in the field of obesity treatment. It is a treatment intended to help patients reduce their body weight in a controlled manner supervised by physicians.
However, it is important to note that this treatment is not inexpensive. According to reports, the price of the drug will hover around 691 shekels for a certain dosage. The high price raises questions regarding the accessibility of the drug for the general public and whether it will be included in the national health basket in the future.
Medical experts emphasize that the use of such drugs must be done under close medical supervision. Before starting use, it is recommended to consult with a family physician to check for personal suitability, ensure there are no dangerous side effects, and understand the effects of the treatment on overall health.
Ahead of the drug's arrival in Israel, pharmacies are expected to prepare for high demand from the public. The Ministry of Health is expected to continue monitoring the effects of the drug and to publish clear guidelines for the patient population.